Feature selection in the prediction of infliximab dose increase

Proceedings of the 9th IASTED International Conference on Artificial Intelligence and Soft Computing, ASC 2005

Volumn , Issue , 2005, Pages 319-324

  Van Looy, Stijn ^a   Meeus, Jeroen ^a   Wyns, Bart ^a   Vander Cruyssen, Bert ^b   De Keyser, Filip ^b   Boullart, Luc ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Feature selection; Real life data; Recursive feature elimination; Rheumatoid arthritis; Support vector machine; TNF blockers

Indexed keywords

BIOLOGICAL THERAPIES; CHRONIC INFLAMMATORY; CLASSIFICATION PERFORMANCE; CLINICAL KNOWLEDGE; DOMAIN KNOWLEDGE; REAL LIFE DATA; RECURSIVE FEATURE ELIMINATION; RHEUMATOID ARTHRITIS;

ARTIFICIAL INTELLIGENCE; DISEASES; FEATURE EXTRACTION; PATIENT TREATMENT; SOFT COMPUTING; SUPPORT VECTOR MACHINES;

FORECASTING;

EID: 84887261382     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (13)

1. P.E. Lipsky, D.M. van der Heijde, E.W. St. Clair, D.E. Furst, F.C. Breedveld, & J.R. Kalden, Infliximab and methotrexate in the treatment of rheumatoid arthritis, New English Journal Med, 343, 2000, 1594-602.
2. P. Durez, F. Van den Bosch, L. Corluy, E.M. Veys, L. De Clerck, A. Peretz, M. Malaise, J.P. Devogelaer, N. Vastesaeger, A. Geldhof, & R. Westhovens, A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study, Rheumatology (Oxford), 44, 2005, 465-468.
3. B Vander Cruyssen, S Van Looy, R Westhovens, P Durez, F Van den Bosch, EM Veys, L De Clerck, A Peretz, M Malaise, J Devogelaer, L Verbruggen, N Vastesaeger, A Geldhof, L Boulart, F De Keyser, "DAS28 correlates best with the physician's clinical judgment of response to Infliximab therapy in rheumatoid arthritis patients.", Accepted at EULAR 2005: Annual European Congress of Rheumatology, Vienna, Austria, June 2005
4. I. Guyon, J. Weston, S. Barnhill, V. Vapnik, Gene selection for cancer classification using support vector machines. Machine Learning, 46(1-3):389-422,2002
5. J.E. Ware Jr., & C.D. Sherbourne, The MOS 36-item short-form health survey (SF-36), I. Conceptual framework and item selection, Med Care, 30, 1992, 473-483.
6. A. Dempster, N. Laird, & D. Rubin, Maximum likelihood from incomplete data via the EM algorithm, Journal of the Royal Statistical Society Series B, 39(1), 1977, 1-38.
7. C. Cortes, & V. Vapnik, Support-vector networks, Machine Learning, 20(3), 1995, 273-297.
8. M. Aizerman, E. Braverman. & L. Rozonoer, Theoretical foundations of the potential function method in pattern recognition learning, Automation and Remote Control, 25, 1964, 821-837.
9. S.S. Keerthi, & C.-J. Lin, Asymptotic behaviors of support vector machines with Gaussian kernel, Neural Computation, 15, 2003, 1667-1689.
10. S. Haykin, Neural Networks a Comprehensive Foundation 2nd edition (Englewood Cliffs, NJ: Prentice-Hall, 1998).
11. T. Kohonen, Self-organizing Maps, 2nd edition (New York, NJ: Springer-Verlag, 1997).
12. Mosier, C. I. (1951) Symposium: The need and the means of cross-validation. I. Problems and design of cross-validation, Education and Psychological Measurement, 11, 1951, 5-11.
13. J. A. Swets. Measuring the accuracy of diagnostic systems. Science, 240(4857):1285-1293, June 1988.